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ABSTRACT
Forty (40) female patients with breast masses underwent Technetium 99m Sestamibi
scintigraphy in order to evaluate its usefulness in differentiating benign from malignant breast
disease and to compare scintigraphy to mammography. Informed consent was obtained from
each patient. Scintigraphy consisted of anterior chest and lateral and oblique breast planar
images, obtained 5 minutes after intravenous injection of20 rna.. curies (740 MBq)
'I'echnetium 99m Sestamibi. Eleven (11) of the 40 patients also had Technetium 99m
Methylene Diphosponate breast scintigraphy for comparison. Four nuclear medicine physicians
of who three also graded the MOP images perfoi..ied grading of the Sestamibi scintigraphic
images. The grading method, although focussing on the absence (0) or presence (>0) of
uptake of isotope, was also designed for comparison of the Sestamibi and MOP images.
Statistical analysis showed good correlation between observer grading. Breast scintigraphy
was compared to mammography in 27 ofthe 40 patients.
Of the 26 malignant breast masses confirmed on histology, 19 were positively identified on
Sestamibi scanning giving a sensitivity of73%, 2 results were inconclusive (grading (JfO·1)
and 5 had a grading ofO. Of the 8 patients with confirmed lymph node metastases, only 2 were
positive on the Sestamibi scans, with 1 inconclusive result. Of the 19 benign breast masses, 9
were visible on Sestamibi scans with additional 3 inconclusive results (grading of 0-1).
Statistical analysis showed no significant difference in the Sestamibi and MDP grading. In
comparison to mammography, breast scintigraphy was less accurate in distinguishing benign
from malignant breast masses. Mammography identified 85.7% of the malignant breast masses
and 72.7% of the benign breast masses. Sestamibi scintigraphy identified 76.2% of the
malignant breast masses and only 36.4% of the benign breast mass-es.
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I.U INTRODUCTION
1.1 Breast Cancer - Overview
Breast cancer is an extremely common disease and causes significant cancer related mortality
each year (1). The incidence rate for women aged 50 ~64 is 160 per 100 000 as compared to
200 per 100 000 for women aged 65-74. (2) Follow up studies show that breast cancer is a
devastating disease, with an annual death rate of around 8% among survivors' even 20 years
after diagnosis (3).
Factors increasing the risk of breast cancer include family history, the presence of the BRCAI
gene, hormones (both endogenous and exogenous), diet, lifestyle (alcohol, smoking, exercise)
and high dose ionizing radiation exposure to the chest (4).
The growth rate of breast cancers is highly variable, but in most cases the disease has been
present for many years before it is detectable by any means. About 40 doublings of breast
cancer cells create a lethal tumour burden, yet mammography cannot detect a mass until 25 -
30 doublings have already occurred (3). Inview of the cytokineticr, of the disease, it is not
surprising that the eventual outcome (death due to breast cancer) for the majority of women is
unaffected by screening mammography (3).
Breast cancer has an unusual age b incidence pattern; it is rare before the age of25, the
incidence increases with advancing age until the age of 45 when a leveling off occurs known as
Clernmesen's hook. After 55, the incidence rate rises again, but more slowly until its apex at 75
years, after which the rate seems to decline (2).
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Breast cancer is a chronic disease because the rising incidence, coupled with the improved
survival rate after effective treatment, has placed an increasing number of women. at risk of
developing cancer in the opposite breast (5,6).
Screening which refers to the IIexamination of asymptomatic people" for chronic disease
therefore applies to breast cancer (7) and includes breast self-examination, education and
diagnostic imaging.
1.2 DiagnosticBreast Cancer Imaging
1.2.1 Mammograpby
Mammography is certainly capable of'identifying abnormalities that may be breast cancer at a
clinicaUyundetectable stage. (3) However, one major drawback to its widespread use is the
financial and emotional cost of the large number of biopsies done for clinically occult benign
lesions. (8)
Mammography's greatest limitation is its low specificity in distinguishing between malignant
and benign lesions and even with the highest quality mammography, 5-10% of cancers may
not be detected mammographic ally (9). These "missed" cancers are frequently caused by
radiographically dense breast tissue (9) or interval cancers (10).
The current exposure from a mammogram is between 200-400 millirads (0.002-0.004 Gy).
The estimated added lifetime risk of breast cancer mortality tor a woman who has annual two-
view mammography from age 50 is 3,9 per 100000 (4). Because of the low accuracy of
mammogrspby and the slightly lower incidence of breast cancer inyounger women, the
economic and clinical feasibility of screening in the 40-49 year age group remains controversial
(9), Biannual mammography for women aged 50 and over is recommended at present.
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1.2.2 Magnetic Resonance Imaging (MRl)
MRI provides multiplanar breast imaging and excellent soft tissue contrast without ionizing
radiation. Dedicated breast surface (Jails improved tile signal-to-noise ratio providing thin,
contiguous imaging slices allowing detection of cancers as small as 3mm. The intravenous
administration of gadolinium contrast agents has also improved cancer detection rates. The
presence of dense fibroglandular tissue is not a limitation for MRI because the contrast
enhancement pattern is reflective of the tissue blood supply and is I".ota function of differential
tissue densities. However due to the high cost of contrast enhanced MRI and its limited
availability, it cannot be viewed as a potential screening method. It is complementary to
mammography and ultrasound (9). At present the rate of'false-negative MRI reports are
unknown and MR1 alone should not be used to exclude the presence of breast cancer (11).
1.2.3 Ultrasound
Sonography is 110t useful for screening for breast cancer because its sensitivity and specificity
are far lower than those of mammograp' .Io-vever, ultrasound examination of a palpable
breast tumour is reliable indifferentiating between benign and malignant (sensitivity of 96%
and specificity of 94%) (12). It can differentiate cystic from solid masses with accuracy
approaching 100% (:;l). Ultrasound ofa palpable breast mass is useful in young women,
pregnancy, after implantation of prosthesis, post-radiation to detect an abscess, to perform
ultrasound-guided fine needle aspiration (lZ}. Ultraso rnd has a definite complementary
function in the management of palpable breast masses.
1.2.4 Radlonuelide imaging
The differential diagnosis between benign and malignant breast lesions has long been a
challenge for many researchers using radioisotope-based techniques. The various isotopes at
present being studied include Technetium 99m Methylene Diphosphonate (MOP), Thallium-
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201, Technetium 99m Tetrafosmin, Technetium 99m labeled synthetic peptides, the glucose
analogue: 2-deoxy-2 .. F18-fluoro-D-glucose (FDG), Indium -111 ootreotide (a somatostatin
analogue) ana Teczneeium 99m Sestamibi. The exact mechanism of cellular uptake of Tc99n1
Sestamibi by cancer cells is unknown. Recent data suggest that 90% of the tracer activity is
concentrated in the mitochondria (13), Organ dosimetry ofT~99m Sestamibi demonstrates
that a dose of20 miuicuries (740 MEq) delivers :3 rad (0.03 Gy) to the large intestine, which is
the predominant target organ. The whole body dose is 300 millirads (0.003 Gy), which is
comparable to mammography (13). The technique of prone breast imaging is more favorable
than the supine position because of excellent separation of deep breast structures from the
myocardium in the left breast and provides natural landmarks of the breast contour that are
necessary for localization oflesions (14,13).
1.3 Literature Review of Scintigraphic Agents Used in Breast Imaging
1.3.1 Thallium 201 (TI201)
T1201 has chemical properties similar to those of potassium ion. As h is a potassium
analogue, uptake ofTl201 into tumour cells depends on the ATPase sodium potassium
transport system. Breast cancers show higher concentrations of potassium than benign lesions
of61 breast (15). The concentration of thallium inbreast cancers seems to be primarily
dependent on vascularity and tumour size. Breast tumours of small size may negatively
influence Ti201scan because of low absolute Tl201 uptake by the tumour (15).
Thallium scintigraphy showed a low sensitivity for detecting lymph node metastases (15,16)
TI 201 appears to have a high sensitivity for the detection of malignancy in palpable breast
masses. However, it cannot differentiate between malignancy and highly cellular
fibroadenomas with accuracy. (17,16)
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201 ill'S a phygk,a! half~Iife of 73. t ileum and a biological haU:Hfe ef 11) days. The kidney is
tile critical crgan, r~i'-'ing 1 rad Gy) per 1-millicur:e CT4 rViliq) dose. The. kmg physical
i1alt:iHe, [jCl1f emission charsci. .•fist1cs f 81) ({.;;v i J.l:1drestricted availability due rc cyclotron
production are definite disadvfuuages fer u.sing this agent.
i,~.l Te;c~Uli!l0t~l!J!1iiil Ralliteierl! ageJil\ltl
Technetium 99m has a physical haif~!iteof 6,02 bours and is available at anv time.
1.~.J!·,~·TeciuililiC1l:il!J!iiiI1 99li1l1f lMfethyEeli1!>Z Dfrp~~®spIlM~li1!~are(ilvIDP)
similar t() those of Ti 2/Ji scintigTaphy were found A specific pattern Qfu~take ofT~''9i)m
MDP' was however found in inflammatery carcinoma, i.e, wen defined focus of'increased
uptake it) early images that decreased in the late images. Infiltrated skin was well delineated.
Conven:cly. acute inflammatory processes ShOWL'ti faint, non-homogenous uptake without
signs ofskiu infiltration (18).
1.3.1.21'echnetium 99m MetiBoxyisobutylisonitrile (Sestamibz)
The WJC IJj"l'c(J()1ll Sestamlbi in tumour imaging was first reported in I (ih9 in lung tumours
(19) and subsequently in thyroid, brain and bone tumours (20).
Prelimlnary studies have shown that a positive Tc99m Sestamibi breast image may indicate It
possible maligeencv, However. highly cellular fibroadenomas were found to exhibit Sestamibi
uptake (21,22) and in one study, (21) two patients with invasive lobular carcinoma showed
absent Sestamibi accumulation. The sensitivity of Sestamibi in detecting axillary metastases
W.H' 1,)\\ ("10 ;1) (21) However, fat necrosis, post-surgery scar fOI'~ •-m, prostheses and dense
{m~as.t"did n~l~interfere with the interpretation of scans as compared to mammography
Tumour size also affects sensitivity of Sestamibi. Lesions < l Omm were undetectable with
Tc99m Sestamibi (23). Reports have varied from: "Tc99m Sestamibi breast scintigraphy is
useful in distinguishing malignancies from benign breast masses" (20) to "mammography and
ultrasound are the basic screening modalities for palpable breast masses and cannot be
replaced by Sestamibi breast imaging" (21).
1.3.3 Indium 11.1 Octreotide
Octreotide is a somatostatin analogue. Somatostatin-receptor (SS-R) scintigraphy shows
primary cancers and distant metastases in most patients with carcinoids, :51et cell tumours and
paragangliomas. Previous in-vitro studies indicated that somatostatin receptors are present in
human breast cancers. By using SS-R scintigraphy those SS-R positive breast cancers could be
demonstrated in vivo as well as any metastases present. Scintigraphy also showed the preSI;tl:c.e
of'metastases 111 symptom-free, initially SS-R po~l!ive, br'east cancer patlents (In tbllow-up
studies. These patients had normal CA15-3 and CEA serum levels (24).
The radioisotope used to label the somatostatin analogue, Indium-Ill, is cyclotron produced
and therefore not readily available. It does however have a physical half-life of2,8 l days with
1'KIron energies of i72 key and 147 kev, allowing delayed imaging of24 to 48 hours.
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2.0 OVERALLAIM OF TillS STUDY
Screening mammography, considered to be a vital defense against breast cancer, is fraught
with controversy and lacks a high degree of diagnostic accuracy. Mammograms are insensitive
to detecting some breast cancers, and can cause false alarms prompting unnecessary biopsies.
These "false-positive" mammograms are physically as welt as psychologically traumatic. All
women experience some anxiety while having a mammogram and frequently suffer more
distress while awaiting the study results. In addition, breast cancer in the elderly women ill
becoming a medical problem of increasing magnitude. Responding to the need for earlier,
more accurate and cost-effective methods of cancer detection, researchers are investigating
adjuvant and alternative methods to traditional screening (9). At present there is clinical
interest, generated by published' .eports, in breast imaging using several radiopharmaceuticals
such as Tc99m Sestamibi, Tc99m Tetrafosmin, T1201, Tc99m 8M3 monclonal antibody and
F18 :FDG. Almost one in five presentations at the 1995 Annual Meeting of the European
Association of Nuclear Medicine in Brussels dealt with oncology and one of the most
prominent issues was breast cancer.
Preliminary results of breast scintigraphic studies are promising, but they generally concern
small series of patients. Because the physical characteristics of Tc99m Sestamibi are more
favorable for scintigraphic imaging than those ofTL 201, the aim of this prospective study
was to validate the use ofTc99m Sestamibi in the diagnostic work-up of patients with breast
disease. Since the breast cancer patients were due to have a routine bone scan using Tc99m
MDP, I initially intended to include a comparison ofTc99m Sestamibi and Tc99m MDP in this
study. However, due to technical problems experienced during this study, at the conclusion of
the study, only eleven completed studies were available for comparison. 11\this study, breast
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scintigraphic imaging was compared to the histological diagnosis obtained via fine needle
biopsy or post surgical excision.
3.0 METHOD
The study protocol was reviewed by the Postgraduate Committee, the Faculty of Health
Sciences of the University of the Witwatersrand. Ethical clearance to perform this study was
obtained from the Department of'F, -nan Ethics (Appendix B).
3.1 Study Sample
25 patients with breast carcinoma (Group A) and 15 patients with benign breast masses
(Group B) gave informed consent to participate in this study (Appendix C). In Group B. three
patients (numbers I, 10 and 14) had bilateral breast masses. InGroup A, one patient had a
benign mass in one breast (included in the results of the benign group) and a malignant mass in
the other breast.
All the patients had either fine needle biopsy or excision biopsy/mastectomy.
Eleven patients in Group A had both a Tc99m MDP scan and a Tc99m Sestamibi scan.
3.2 ImagingMethod
Each. patient received 20 millicuries (740MBq) Tc99m Sestamibi, inj~cted intravenously in the
arm opposite to th~ breast with the abnormality. If'both breasts had abnormalities, the arm
opposite to the breast with the larger abnormality was used. Imaging was commenced five
minutes postinjection.
An anterior chest image was obtained in the upright position with the arm raised inorder to
view the axillae. The patient was then positioned prone with the breast pending and a lateral
and posterior oblique image was obtained of the breastls with an abnormality. A lateral image
only was performed of the opposite breast if there was no known abnormality.
Scintimammography was performed using a gamma camera equipped with a high-resolution
collimator. Acquisition parameters included: 1) a 10% window centred on a 140 kev
photopeak and 2) static imaging for 1 million counts for the anterior view ana 2 million counts
for the prole views 3) zoom factor of 1.5 for the lateral views.
This procedure required approximately 40 - 50 minutes.
The patients who also had a Tc99m MDl-' scan, were having a routine bone scan as part of
their metastatic work-up. The breast imaging was performed fifteen to twenty minutes
postiniection using the same technique as for Tc99m Sestamibi, Due to difficulties experienced
trying to coordinate timing and gamma camera availability, only eleven completed Tc99m
MDP studies were obtained.
4.0 RlESULTS
Four nuclear physicians, independently, without prior knowledge of the clinical or histological
data, performed the interpretation and grading of'the scintigraphic scans (Appendix D).
Observers were allowed to discuss the scintigraphic grading method prior to being given the
study material, thereby trying to minimize variation between observer grading. All four
observers used a modem (grey scale) and not X-rays to interpret the results, So as to produce
a uniform standard of grading. Tho scintigraphic grading of the scans was performed as
defined ID.Table 1. this grading method was decided on after discussions with various nuclear
physicians and breast surgeons. Initially I looked at using a region of'mterest (ROI) and
calculating a target-to-background ratio, however after testing this method using the
departmental registrars, lack of consistency in the results led to favoring the selected method
(breast size variation also made it difficult to standardize a ROI). Although the focus is on the
presence or absence of uptake cr' the isotope, the 0 to 3 grading was used with the intention of
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comparing the uptake of Tc99m Sestamibi with Tc99m MDP and (for interest only) to assess
whether the size of the lesion had any effect on the intensity of uptake.
TABLE 1 - SClN'rIGRAPIDC GRADING
e NO FOCAL UPTAKE OF ISOTOPE
1 PRESENCE OF SLIGHTLY INCREASED UPTAKE OF ISOTOPE
2 DEFINITE INCREASED UPTAKE OF ISOTOPE
3 INTENSE INCREASED UPTAKE OF ISOTOPE
Most patients presented with breast masses with the exception of the following patients in
Group A:
• Patient number 4 presented with a persistent nipple discharge. Cytology smears were
repeatedly negative. A mastectomy was performed at the patient's request. Histology
showed Paget's disease with an underlying duct cell carcinoma-in-situ behind the nipple.
Although Paget's disease of the breast is uncommon, it accounts for 1-4 % of all breast
cancers and was found to be associated with an underlying carcinoma in situ which is often not
evident prior to surgery (8). Both Sestamibi and MDP gradings were positive (>0).
• Patient number 6 had had bilateral mastectomies followed by prosthetic breast implants,
because ofa strong family history of breast cancer. Now she presented with a painful
palpable lymph node in the left axilla, which on biopsy was found to be malignant. She
subsequently had surgical removal of all remaining breast tissue and axillary clearances.
Only the left axillary node was found to be malignant on histology.
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The Sestamibi scan was negative for lymph node detection in this patient.
ilJ Patient number 23 presented with enlarged left axillary nodes and an inflamed swollen left
breast. FNA of the axillary nodes showed duct cell carcinoma but the breast biopsy was
negative for malignancy. Both the Sestamibi and the:MOP grading for breast masses are
inconclusive, since they vary frem a grading of 0 to 2. Two observers rated the Sestamibi
scans positive for lymph nodes. The MOP gradings were all negative for lymph nodes .
., Patient number 24 had previously had a left mastectomy and now presented with a mass in
the right breast. Duct cell carcinoma was diagnosed on fine needle aspiration, but only
proliferative breast tissue was found on histology post mastectomy. She has been included
in the malignant group of patients. The Sestamibi scan of the right breast showed only
slightly increased uptake of isotope (Grade 1).
Interobserver reliability test results:
The statistical analysis (Appendix E) shows a good correlation between observers (Z~value
significantly greater than 1.96) for breast mass grading. Lymph node grading was less
consistent (Z-value ofless than 1.96).
Of interest, was that all four the observers found uptake of isotope in the opposite breast
tissue of two of the patients in the benign group, neither of whom had palpable masses in these
breasts. One patient had mammography which was negative.
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TABJ.£ 2 - GROUP A (CARCINOMA)
'Patio. ·r AGE BREAST TUMOUR MAMMOG. MISi MOP HISTOI.OGY NODES
YI'S Size Lesion Nodes Lesion Nodes Histology
1 S.C sa LEFT 2,4 X 2,4 cm SuspicIous 0 Negative Malignant
RIGHT 5X4,5cm Suspicious 3 NegatiVe Mallgr.an!
:2 CdeB 50 RIGHT 2,5X2cm 3 Positive Mafignant Positive
3 AD S1 LEfT 3X3cm 0-1 Negative Malignant
4 EAD 2B RIGHT nipplediso Notsuspic. 1-2 Negative 2 neg Malignant
5 MF 00 RIGHT 6X6cm Def.Malig. 1-2 Negati~e 2 Pas/neg Malignant Positive
e VF 53 LEFT NODE 0 Negative I\.lalignant P()Sitlve
AXIL
7 MCG 70 LEFT under 1 em Suspicious 0 Negative Malignant,
RIGHT 2,4cm Benign 0 Negative Benign
8 liH 65 LEFT 8cm Def.mallg. 3 Poslneg Malignart.
9 ZK 55 LEFT app.1 em Sf.I$piciaus 0 NegaUve 0 neg Malignant
10 CM 3S LEFT 3,3X1,1cm Suspicious 1-2 Poslneg MaUgnan!
11 JRM 78 RIGHT 2,5X2cm SuspIcious 1-2 Negative 1·2 neg Malfgnant Positive
12 MM 59 LEFT peaud'oran Suspicious 2-3 Pas/neg 2 neg Malignant
13 EM 54 LEFT 2,1 X 2,5 em Suspicious 2 Negative 2 neg Malignant
14 BM 71 LEFT Scm 3 Positive Malignant
15 EN ss LEFT 2X2,5cm Defmalig 2-3 Positlve 1 neg Malignant Posi!i'Je
16 WP 46 LEFT Suspicious 0 Negative Malignant
17 MP 32 LEFT 5X4cm SU!>picious 2 Negative Malignant Positive
18 AR 39 LEFT mote 10cm Suspicious 2 Positive Malignant
19 AJS 68 LEFT 2,4Xl,6cm Slispicious 1-2 Negative Maligner,t
20 SS 53 RIGHT 3,5X2,5cm Suspicious 1-2 Negative 0-2 neg Mali9nanl
21 MT 47 LEFT 4X4cm 3 PosttlVe Malignant
22 CvH 54 RIGHT !,~OX1,1cm Benign 1 Negative 2 neg Malignant Pcsitive
23 RV 59 LEFT Notsuspic 0-1 Poslneg 0-1 neg Malignant Pcsltive
24 MvZ 79 RIGHT SuspIcious 1 Negative Malignant
25 BGZ 35 LEFT 3X3cm Suspicious 2 Negative (\.1 neg Malignant
-
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TABLE 3 - GROUP B (BE~""'IGN)
PATIENT AGE BREAST TIlMSlZE lWAMISON MIBIGMD MIBIGRAl) HISTOl.OGY
Yrs ems Lesion Nodes
1 JMB 33 LEFTX2 U.5XO,3XO,7 Probable cyst Q Negative Cyst
3,3x1 ,4x1 ,5 Fibroadenoma 1-2 Negative Fiaroadenoma
2 HdS 39 RIGHT 4X2,5 Suspicious 2 Nec':tive Fibruadancma
3 GK 48 RIGHT 3X4,5 Oef 3 Negative Chron
malignant abscess
4 SM 20 LEFT 4x2 Suspicious 0-1 Negative Fibroadenoma
5 GM 53 RIGHT Benign 0 Negative Benign
6 CM 36 r.IGHTX2 Benign 0 Negative Benign
7 EM 2B LEFT I 0 NegatiVe Fibroadenoma
8 ™ 18 LEFT 1-2 Negative Fibroadenoma
9 EM 46 RIGHT 0-1 Negative Fibroadeno!T'.a
10 OM 20 LEFT 0-1 Negative Benign
RIGHT 2 Negative Fibroadenom;a
11 VM 24 RIGHT 0 Negative Fibroadenoma
12 NM 35 RIGHT 1,5X1,2XO,5 Benign 1 NllGative Fibroadenllma
13 KR 41 LEFT 1 Negative Cyst
14 OS 41 LEFT 1,8X1 Prob benign 1-2 Negative Benfgn
1
RIGHT Prob benign 1 Negative Fibroadenoma
15 HvA 53 RIGHT 0 Negative Fibroadenoma
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4.1 Tc99m Sestamibi vs Pathology
Of the 26 malignant breast masses confirmed on histology, 19 were positively identified on
Sestamibi scanning giving a sensitivity of 73%, 2 results were inconclusive (grading of 0-1)
and 5 had a grading of O, No correlation was found between the size of the lesion and the
degree of uptake ofisctope.
Of the 8 patients with confirmed lymph node metastases, only 2 were positive on the
Sestamibi scans, with 1 inconclusive result.
Additional 3 patients, who did not have surgery, (i.e. lymph node metastases not confirmed)
showed lymph node involvement on Sestamibi scans. All 3 patients had palpable lymph nodes.
Of the 19 benign breast masses, 9 were visible on Sestamibi scans with additional'S
inconclusive results (grading ofO-I). Interestingly, the patient with the chronic breast abscess
had a grading of3, suggesting that inflammation could be a cause of incteased uptake of
isotope. This gives a false positive value of 47A%-61%. This high false positive value is in
contrast to previous studies. Inthe study done by Khalkhali et al (13) only 5 out of33 benign
breast lesions were false positives; of these 2 were fibroadenomas. The study by Kao et al (20)
showed all 6 benign masses as true negatives; all 6 were fibrocystic disease. Inthe study by
Burak et al (21) 2 of 14 benign masses were false positives; both were fibroadenomas. Again
in tbe study by Lu, Shih et al, (22) 4 of 7 fibroadenomas were false positives and this led them
to conclude that fibroadenomas with hypercellularity may cause false positive Sestamibi scans.
In the study by Tabuenca (26) 10 of 13 benign masses were positive on Sestamibi scans, but
they concentrated on the 3 becoming true positives.
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In this study, the statistical analysis (Appendix E) clearly demonstrates that Sestamibi imaging
cannot differentiate between benign and malignant breast masses with accuracy. Although the
statistical analysis of lymph node detection by Sestamibi imaging compared to histology
correlated, the numbers are small (only 8 confirmed) and should be interpreted with caution,
since the interobserver grading oflymph nodes showed poor correlation.
Thus, although the sensitivity of Sestamibi for detecting palpable breast masses is good, the
specificity is very low. Lymph node detection is also poor and only positive inquite advanced
breast carcinoma.
Breast scintigraphy, however, is unaffected by breast density or the presence of scar or fibrous
tissue as these did not influence or interfere with the interpretation of these scans.
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TABLE 4 - SESTAMmI vs, MD]>
PATIENT AGEYR5 BREAST MIBI-Iesloo MIBl-IlQdes MD?-Ieslon MDP-nool!S HISTOLOGY NODES
f EAD 28 RIGHT 2 NegatiV<l 1-2 Negative Malignant
2 MF 60 RIGHT 2 Negative 1-2 2negllpol; Malignant PO$itive
3 ZK 55 LEFT 0 Negative 0 Negative Maflgnant
4 JRM 78 RIGHT 1-2 Nega:ive 1-2 Negative Maflgnant Pc:siJive
. .-
5 MM 59 LEFT 2-3 Negative 1-3 Negative Malignant
6 EM 54 LEFT 2-3 Negative 1-3 Negative Malignant
-7 EN 35 LEFT 2-3 2pG"Jlneg 1 Negative MalY;;;r.mt I Positive
8 55 53 RIGHT 1-2 NegatiV<l 0-2 Ncgalivfl Malignant
9 CvH 54 RIGHT 1-2 Negative 1-3 Negative Malignant Positive
10 RV 59 LEFT 0-2 2posJlneg 0-1 Negative Malignant Posil.ive
11 BGZ 35 LEfT 1·2 Negative I 0-1 NegatiV<l Malignanti
4.2 Tt99m Sestamibi VsMDP
Only the results of 3 ofti'le observers were used (1 did not receive the MDP images and
therefore did not grade them).
The statistical analysis showed a good correlation between the Sestamibi and lVIDPgrading.
Due to the small sample size, this would have to be confirmed by a larger study.
The hypothesis that the mechanism of uptake of Tc99m MDP may be due to increased
vascularisation or inflammatory change (18) may account for the slight difference in grading in
Paget's disease (however, it would have been interesting to compare the uptake in the chronic
abscess).
Sestamibi showed a slightly better detection of'lymph nodes than MOP. This is consistent with
the study done by S. Lastoria et al (27), which concluded that Sestamibi better depicts lymph
nodal infiltration.
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4.3 Scintigraphy Vs Mammography
Mammography was performed in 27 patients who also had scintigraphy. There were 32 breast
masses as 5 patients had bilateral masses.
Of the 21 histologically confirmed malignant breast masses, 16 were detected by Sestamibi
(plus 1 inconclusive result) compared to the 18 found to be either suspicious or malignant on
mammography.
Of the 11 histologically confirmed benign breast masses, 8 were benign on mammography
compared to only 4 (grading of 0) on Sestamibi imaging.
In the study by Burak et a1 (21), comparing Sestamibi scanning to mammography and
ultrasonography, all the malignant breast masses were detected by mammography with
ultrasonography. Sestamibi scanning detected 25 ofZ7 malignant masses. The differential
diagnosis of fibroadenomas was however, still more accurate on mammography compared to
Sestamibi scanning. This correlates with the findings in this study.
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5.0 DISCUSSION AND CONCLUSION
5.1 Value and Usefulness ofScintimammography
The results of this study shows clearly that scintigraphy is not accurate in distinguishing benign
from malignant breast masses, nor in detecting lymph node lr" .astases,
Scintigraphy can, however, playa complementary role to mammography, especially in the
patients with dense breast tissue, the post surgical patient with a suspicious breast mass, the
patient who has had radiation therapy and in the patient with breast prosthesis. As observed in
this study, these did not interfere with the interpretation of the scans. Scintigraphy cannot be
used to diagnose or exclude malignancy, but can therefore be more useful in localizing the
mass in the presence of dense breast tissue, scar tissue or prosthesis,
Due to the high false positive results, the objective to determine the extent of the disease was
abandoned as tins would only have been relevant if scintigraphy showed a high sensitivity and
specificity in detecting breast malignancy.
At present, mammography is the most effective method of detecting breast abnormalities and
in conjunction with sonography, (especially ultrasound guided fine needle aspiration) the most
accurate cost-effective method for Jifterentiating benign fuun malignant masses.
Ultimately the definitive diagnosis is still made on cytology or histology.
5.2 Future of Breast Imaging
At present, interesting research is being done on the feasibility of imaging using monoclonal
antibodies and labeled receptors. If, for example, somatostatin receptor scintigraphy is
effective in the early detection of somatostatin- receptor-positive breast cancer, it may have
future use in the selection of patients who can be treated with somatostatin analogues or
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radiotherapy using an alpha-emitting or beta-emitting radionuclide coupled to a somatostatin
analogue (24). Positron emission tomography (PET) using the glucose analogue: F18-2-
fluoro-z-deoxy-Deglucose (FDG) or Cl l-methionine inbreast cancer scintigraphy cou1d be
useful in providing early information 011 the efficacy of chemotherapy, allowing earlier
adaptation of therapeutic strategies. PET using FDG or Cl l-rnethionine has been effective in
identifying primary breast tumours, axillary lymph node metastases, pleural and hepatic
metastases (28,29). Another possible application of PET, is to study dynamic changes over
time, including metabolic changes in the tumour (29).
Digital mammography, although still in the developmental stage, uses the direct digital capture
of the mammographic image with an electronic detector (vs. film); this allows more flexible
mapping and display of radiographic densities (30). It has several advantages and
disadvantages.
Advantages include: a) improved image quality especially of those patients with dense breast
tissue. b) computer-aided diagnoses. c) digital images that can be transmitted via telephone or
internet for rapid expert interpretation.
The main disadvantage is that the digital technique can cover only a small area of the breast at
a time and has limited spatial resolution (31,30).
Colour-coded as well as spectral doppler ultrasound is also being evaluated as a possible
supplementary diagnostic tool for differentiating benign from malignant breast masses,
especially as a means of reducing the number of unnecessary exploratory biopsies (32).
Colour-coded doppler sonography visualises the vascularity of breast masses. Tumours as
small as 3mm rely on the formation of capillary vessels for further growth which can be
imaged by highly sensitive colour-coded doppler units (32). Colour-coded doppler ultrasound
is also being assessed as a potential technique for detecting axillary lymph node metastases (1).
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Hopefully, with the integration of all these new technologies, and continued research, the
detection and diagnoses of early breast cancer will become more accurate.
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APPENDlIXA
EXAMPLES OF SClNTIGRAPIDC IMAGES
Fibroadenoma (four views) - Sestamibi Grading 2
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Chronic breast abscess - Sestamibi Grading 3
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Fibroadenoma - Sestamibi Grading 2
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Fibroadenoma - Sestamibi Grading 1
26
Carcinoma - Sestamibi Grading 3
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Carcinoma - Sestamibi Grading 2-3
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Carcinoma - Sestamibi - Grading 1-2
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Carcinoma - MDP - Grading 1-3
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ROLE OF BREAST SCINTIGRAPHY IN CANCER
Patient Information and Consent (Breast Cancer)
Because you have diagnosed breast cancer, I am asking you to participate in this research
study to determine if radioisotopes can be useful to detect breast cancer. As your diagnosis has
already been established. it will not be useful to you but may be offuture benefit to other
patients.
Ifyou participate you will have a 20mCi Tcc99m Sestamibi injection followed by a scan of
both breasts. This will involve lying face down for approximately twenty minutes and standing
with arms raised for five minutes. Your privacy will be ensured by means of closed doors.
adequate clothing and female staff only. Tc99m Sestamibi is a radioactive isotope but the
lowest possible dosage is used to ensure minimal exposure to radiation (Tc99m Sestamibi has
been safely used in many studies).
We are unable to use radioisotopes during pregnancy or ifyou are breastfeeding
Possible adverse effects include:
1) Short-lived metallic or bitter taste after injection.
2) Short-lived headache, flushing or non-itching rash.
Other rare adverse effects include possible seizures, short-lived arthritis of the wrists and
allergic reactions.
We shall need to do a routine bone scan which is not part of this research, but is necessary as
part of the investigations into your condition.
Participation in this study is voluntary and you are free to retuse to participate or to withdraw
your consent and to discontinue participation at any time. Ifyou decline or withdraw from this
study it will not affect your treatment or medical care in any way. A signed copy of this
consent form will be made available to you.
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ROLE OF BREAST SCINTIGRAPHY IN BREAST CANCER
Patient Information and Consent (Benign Condition]
Because you do not have breast cancer, but do have a breast mass, I am asking you to
participate in this research study. so that I can compare benign breast conditions to breast
cancer using radioisotopes. This will enable me to establish the usefulness of radioisotopes in
detecting breast cancer. Therefore, it may not be of use to you now, but hopefully will be of
future benefit to other patients.
Ifyou participate you will have a 20mCi Tc99m Sestamibi injection followed by a scan of both
breasts. This will involve lying face down tor approximately twenty minutes and standing with
arms raised for five minutes. Your privacy will be ensured by means of closed doors, adequate
clothing and female staff only, Tc99m Sestamibi is a radioactive isotope but the lowest
possible dosage is used 1;0.) ensure minimal exposure to radiation (Tc99m Sestamibi has been
safely used in many studies).
The scan results will be discussed with you.
We are unable to use radioisotopes during pregnancy or if you are breastfeeding.
Possible adverse effects include:
1) Short-lived metallic or bitter taste after injection.
2) Short-lived headache, flushing or non-itching rash.
Other rare adverse effects include possible seizures, short-lived arthritis of the wrists and
allergic reactions.
Participation in this study is voluntary and you are free to refuse to participate or to withdraw
your consent and to discontinue participation at any time. If you decline or withdraw from this
study it will not affect your treatment or medical care in any way. A signed copy of this
consent form will be made available to you.
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ROLE OF BREAST SCINTIGRAPHY IN BREAST CANCER
Patient Information and Consent (Possible Recurrence)
Because you have had breast cancer and this method may be useful in detecting a recurrence, I
am asking you to participate in this research study. At present I am trying to establish the
usefulness of radioisotopes in detecting breast cancer. Therefore, it may not be of use to you
now, but hopefully will be of future benefit to other patients.
Ifyou participate you will have a 20mCi Tc99m Sestamibi iniection followed by a scan of both
breasts. This will involve lying face down for approximately twenty minutes and standing with
arms raised for five minutes. Your privacy will be ensured by means of closed doors, adequate
clothing and female staff only. Tc99m Sestamibi is a radioactive isotope but the lowest
possible dosage is used to ensure minimal exposure to radiation (Tc99m Sestamibi has been
safely used in many studies).
We are unable to use radioisotopes during pregnancy or ifyou are breastfreding
Possible adverse effects include:
1) Short-lived metallic or bitter taste after injection.
2) Short-lived headache, flushing or non-itching rash,
Other rare adverse effects include possible seizures, short-lived arthritis of the wrists and
allergic reactions.
We shall need to do a routine bone scan which is not part of this research, but is necessary as
part of the investigations into your condition.
Participation in this study is voluntary and you are free to refuse to participate or to withdraw
your consent and to discontinue participation at any time. Ifyou decline or withdraw, from
this study it will not affect your treatment or medical care in any way. A signed copy of this
consent form will be made available to you.
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I have fully explained the procedures, identifying them as investigational and have explained
their purpose. I have asked whether or not any questions have arisen regarding the procedures
and have answered the questions to the best of my ability.
Date: .
Doctor: .
Ihave been fully informed as to the procedures to be followed and have been given a
description of'the attendant discomforts and risks to be expected. Insigning this consent form
I agree to participate inthis method ofinvestigation and I understand that I am free to refuse
to participate or to withdraw my consent and discontinue my participation in the study at any
time. I understand also that ifI have any questions at any time they will be answered.
Date: .
Patient: ..
Witness: .
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OBSERVER RESULTS
38
Observer Grading Comparison for Tc99m Sestamibi ant! MDP (GK'OUp A)
Patient AGE BREAST MiSt MDP
IObservers
HISTOLOGY hlSTOLOGY
Ob'ilP.iVSrs(4) QbSp.iVers ObsciVers(31
YIS Lesion Nodes Lesion Node. Lesfon Nodes
1 S.C 58 LEFT 0000 Negative Malignant
RIGHT 3333 Negative Malignant
~.
2 CdeB &l RIGHT 3333 4positive M/1lignant Positive
I- 3 AD 51 LEFT 0101 Negative Malignant
4 EAD 28 RIGHT 1221 NegatiVe 222 Negative Malignant
5 MF 00 RIGHT 1221 NegatIVe 222 2Neg/lpos MaUgnant Positivi:
6 VF 53 LEFT 0000 Negative Malignant Positive
AXIL
7 MeG 70 LEFT COOO Negative Malignant --
RIGHT COOO Negative benign
8 HH 6$ LEFT 3333 3negJ1pos Malignant
9 ZK 55 LEFT 0000 NegatJve 000 Negaiive Malignant
10 eM 38 lEFT 1222 3Neg/lpos Malignant
11 JRM 78 RIGHT "1221 Negative 112 Negative Ma!ignant Positive
12 MM 59 LEFT 3321 Negative 232 Negstive Mill~nt
13 EM 54 LEFT 2232 Negative 123 Negativa Malignant
14 BM 71 LEFT 3333 4positlve Malignant
15 EN 35 lEFT 3322 3posflneg 111 Negative Malignant Positive
16 WP 45 LEFT 0000 Negative Malignant
17 MP 32 LEFT 2232 Negative Malignan! Positive
18 AR 39 LEFT 2232 4positlva Malignant
19 AJS 68 lEFT 1122 Negatlv!) Malignant
20 55 53 RIGHT 1221 Negative 022 Negative Malignant
21 MT 47 LEFT 3332 4positive Malignant
22 Cv~1 54 RIGHT 1211 Negative 132 Negative Malignant Positive
23 RV 59 LEFT 0210 1posl3neg :111 Negative Malignant Positive
24 MvZ 79 RIGHT 1111 NegatiVe Malignant
25 BGZ 35 LEFT 1222 Negative 011 Negative Malignant
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Ollserver Grading Comparison for Tc99m Sesramibi (Group B):
PATIENT AGE BREAST MIBIGRAD MlBIGRAD HISTOLOG"
Obsenlers(4) Ob:s:!rvers(4)
Yrs Lesion Nodes
1 JMB 33 LEFTX2 0000 negative cyst
1221 negative fibroadenoma
2 HdS 39 RIGHT 2222 negative fibroadenoma
3 GK 4a ~IGHT S333 negative chron aoscess
4 SM 20 LEFT
.
0110 ~1egalive fibroadenoma
5 GM 53 RIGHT ooao n~gative benign
6 eM 36 RIGHTX2 CXlOO negative beniCJn
7 EM 28 (.EFT CXlOO negative fibroadetlQma
8 TM 18 LEFT 1121 negative fibroadenoma
9 EM 4a RIGHT 1110 negalive fibroadenoma
10 OM 20 LEFT 1001 negalive benign --
RIGHT 2227 negative fibroadenoma
11 VM 24 RIGHT 0000 negative fibroadenoma
12 NM 35 RIGHT 1111 negativr" fibroadenoma
13 KR 41 LE;FT 1112 negative cyst
14 OS 41 l",FT 2121 negative benign
RIGHT 1111 negative fibroadenoma
Iibroade~..1ia15 HvA 53 RIGHT COOO negative
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1. Inter-rater r ability tests:
Right side:
Category PROP. Kappa StDev Z-value
0 0.60 0.89 0.2601 3.43
1 0.19 0.61 0.1598 3.85
2 0.12 0.46 0.1556 2.96
3 0.08 0.92 0.1589 5.76
Overall results:
r-------------------~------------------I~----------------~
1~1-'~np~p-a--------------~S-t-D-e-v-------------_+z...--v-al--u-e------------__
10.74 0.0754 j9.83
Left side:
Category PROP. Kappa. St Dev Z-vaJue
0 0.56 0.75 0.2425 3.09
1 0.17 023 0.1574 1.47
2 0.17 0.26 0.1574 1.66
3 0.11 0.49 0.1560 3.17
--
Overall result:
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Nodes:
Category PROP. Kappa StDev Z-value
Present 0.85 0.75 0.4650 1.60
Absent 0.15 0.75 0.1562 4.77
Comment:
The Z -value is greater than 1.96 for breast masses, therefore there is a strong correlation
between observer results. The Z-va!ue for node detection is <1.96.The correlation between
observers for node detection is poor.
k Comparison of Sest.amibi with histology:
Sample size is adequate to perform binomial distribution test approximating the normal
distribution.
Results:
Condition Grading Frequency 1 Prop z-,;due P-value
Benign 0 ;;4
~33
39.4576 0
Benign >0 41 67 47.5812 0**
Malignant 0 32 0.23881 27.7831 0**
Malignant >0 102 0.76119 88.5585 0
I
43
**Note: The Z-values are large and the P-va1ues are small. This means that the given
proportions are significantly greater than zero, meaning that there is no significant difference
between benign and malignant in the grading.
Node detection analysis:
Frequency Percent Histology- Positive Histology-Negative Total
Grading-Positive 4.81 8.56 13.37
Grading-Negative 20.86 65.78 86.63
Total 25.67 74.33 100.00
-Statistlc DF Value Probability
Chi-Square 1 1.614 0.204
Likelihood Ratio Chi-Square 1 1.519 0.218
Continuity Adj. Chi-Square 1 1.050 0.306
Mantel-Haenszel Chi-Square 1 1.606 0.205
The results show no significant difference between histology and the rater's scores on nodes.
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3. Sestamibi vs MOP:
Frequency Cell ---~--c-'"-.
Chi-Square 0 1 2 3 Tot
-MDF' 6 12 12 3 3
-SESTAMIBI 4 8 17 4 33
Total 10 20 29 7 6
Statistic
0.528
ValueI
L ----.-,-----IChi-Square~~~~~~~_._~-----+---------------Likelihood RaI.;O Chi-Square 3 4, 213
DF
3 2.205
1-----:-:-:-::----:-:::-:--:::------1- ~---~+----.~-~+---,-.--.-
Mantel-HaenszelChi-Square 1.580 0.209
The results show no significant difference between Sestamibi and MOP at the 5% level.
al
3
Prob
0.531
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